The collaboration integrates data from the ProSomnus RPMO₂ into MonitAir’s platform to support longitudinal tracking.
Key takeaways:
- ProSomnus and MonitAir have collaborated to integrate data from the ProSomnus RPMO₂ OSA Device into the MonitAir remote monitoring platform.
- The integration allows healthcare providers to view, organize, and monitor patient oxygen saturation and pulse rate over multiple nights.
- The partnership aims to address night-to-night variability in obstructive sleep apnea by providing continuous physiologic data to inform clinical decision-making.
ProSomnus Sleep Technologies and MonitAir LLC are collaborating to support connected, longitudinal, and personalized care for patients with obstructive sleep apnea (OSA).
Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ OSA Device will be able to view, organize, and remotely monitor patient data within the MonitAir platform. The integration is intended to facilitate clinical visibility into patient status over multiple nights and to support the coordination of care across clinical workflows.
The FDA Class II cleared ProSomnus RPMO₂ OSA Device incorporates a pulse oximeter embedded into the buccal mucosal region of a maxillary dental overlay, intended to measure, display, store, and transmit oxygen saturation and pulse rate. The device is designed for continuous data collection during use in clinical and home settings.
MonitAir’s FDA-registered, HIPAA-compliant platform integrates remote physiologic monitoring, remote therapeutic monitoring, and chronic care management capabilities into a unified workflow. The platform aggregates data from connected devices and provides tools for data visualization, compliance tracking, and communication, supporting clinicians in managing patients with sleep-related and respiratory conditions.
“Despite well-documented health, quality of life, and economic consequences, OSA remains undertreated due to fundamental limitations in how the condition is measured and managed—including night-to-night variability, reliance on frequency-based metrics that may not fully reflect health risk, and limited connectivity between patients and providers,” says Len Liptak, CEO of ProSomnus Sleep Technologies, in a release. “Our collaboration with MonitAir is designed to address these limitations in OSA care by enabling longitudinal remote monitoring of physiologic data generated by the ProSomnus RPMO₂ OSA Device—supporting a more connected, data-driven, and personalized approach to care and helping expand access to treatment.”
“Effectively managing obstructive sleep apnea requires continuous, actionable insights, not just a single snapshot in time,” says Edward Mezerhane, MD, CEO of MonitAir LLC, in a release. “By integrating the high-fidelity data from the ProSomnus RPMO₂ OSA Device directly into MonitAir’s comprehensive monitoring platform, we are giving clinicians the longitudinal visibility they need. This partnership bridges the critical gap between the patient’s home use and the provider’s clinical decision-making, empowering practices to optimize therapy, track compliance seamlessly, and deliver a higher standard of personalized care.”
Remote monitoring services may support:
- Longitudinal monitoring of patient status, including variability across nights and treatment periods.
- Structured documentation of remotely collected data.
- Patient engagement and communication through supported digital tools.
- Care coordination across stakeholders.
